Probing Akt-Inhibitor Interaction by Chemical Cross-Linking and Mass Spectrometry

Bill X. Huang and Hee-Yong Kim

Laboratory of Molecular Signaling, NIAAA, NIH, Bethesda, Maryland, USA

The serine/threonine kinase Akt is a critical enzyme that regulates cell survival. As high Akt activity has been shown to contribute to the pathogenesis of various human malignancies, inhibition of Akt activation is a promising therapeutic strategy for cancers. We have previously demonstrated that changes in Akt interdomain arrangements from a closed to open conformation occur upon Akt-membrane interaction, which in turn allows Akt phosphorylation/activation. In the present study, we demonstrate a novel strategy to discern mechanisms for Akt inhibition based on Akt conformational changes using chemical cross-linking and ^{18}O labeling mass spectrometry. By quantitative comparison of two interdomain cross-linked peptides, which represent the proximity of the domains involved, we found that the binding of Akt to an inhibitor (PI analog) caused the open interdomain conformation where the PH and regulatory domains moved away from the kinase domain, even before interacting with membranes, subsequently preventing translocation of Akt to the plasma membrane. In contrast, the interdomain conformation remained unchanged after incubating with another type of inhibitor (peptide TCL1). Subsequent interaction with unilamellar vesicles suggested that TCL1 impaired particularly the opening of the PH domain for exposing T308 for phosphorylation at the plasma membrane. This novel approach based on the conformation-based molecular interaction mechanism should be potentially useful for drug discovery efforts for specific Akt inhibitors or anti-tumor agents. (J Am Soc Mass Spectrom 2009, 20, 1504–1513) © 2009 American Society for Mass Spectrometry

Akt (also named protein kinase B), a serine/threonine kinase, plays a crucial role in diverse cellular processes involved in apoptosis, proliferation, and diabetes [1–3]. The primary function of Akt is to promote cell survival by phosphorylating and inhibiting a number of downstream pro-apoptotic factors such as Bad, caspase-9, and forkhead transcription factors [4–6]. An elevated Akt activity has been found in a wide spectrum of human malignancies, including prostate, breast, lung, ovarian, pancreatic and colorectal cancers [7, 8]. On the other hand, inhibition of Akt activation has been shown to induce cancer cell death in preclinical and clinical studies [9–11]. These attributes have made Akt a potential pharmacological target for cancer therapy [12] and triggered extensive studies on the detailed molecular mechanism of Akt activation [13–16] as well as the search for specific Akt kinase inhibitors [17–19].

Three highly homologous Akt isomers (Akt1, Akt2, and Akt3) have been reported in mammals. Each isomer is composed of three distinctive regions including an N-terminal pleckstrin homology (PH) domain (residues 1–120), a C-terminal regulatory domain (residues 410–480), and a central kinase domain (KD) [16, 20, 21]. The

activation of Akt is mediated by membrane phosphatidylinositol 3,4,5-trisphosphate (PIP3), which is generated from 4,5-phosphatidylinositol bisphosphate (PIP2) by phosphoinositide-3 kinase (PI3K) upon growth factor stimulation. The binding of PIP3 to the Akt PH domain anchors cytosolic Akt to the plasma membrane, where Akt is activated by phosphorylation of T308 and S473 by phosphoinositide-dependent protein kinases (PDKs) [22–25]. It has been well established that the Akt-membrane interaction is a crucial step for the activation. The interaction not only brings Akt into contact with the membrane-bound PDKs, but also results in conformational changes of Akt that are required for its phosphorylation and activation by the upstream enzymes. It has been recognized that the PH domain blocks access of the upstream kinase to T308, and this structural hindrance appears to be removed by the binding of the PH domain to PIP3. This membrane-dependent conformational change is supported by X-ray crystallography, NMR [26–28], in-cell fluorescence lifetime imaging microscopy [29], and, more recently, chemical cross-linking and mass spectrometry [15].

In the past years, chemical cross-linking mass spectrometry has emerged as a useful tool for probing protein conformation in physiologically relevant conditions [30]. The spatial distance information provided by the MS-determined cross-linking sites of amino acid residues has been shown to be valuable for the elucidation

Address reprint requests to Dr. H.-Y. Kim, Laboratory of Molecular Signaling, Section of Mass Spectrometry, NIAAA, NIH, 5625 Fishers Lane Room 3N-07, Bethesda, MD 20892-9410, USA. E-mail: hykim@nih.gov

tion of protein structural changes associated with protein functions [31, 32]. In an attempt to understand the molecular basis of Akt activation, we have recently developed a technique combining tandem mass spectrometry, lysine-specific chemical cross-linking [15], and proteolytic ^{18}O digestion [33–35] to probe conformation of the full-length Akt for which the crystal structure is not yet available. We demonstrated that Akt undergoes dramatic interdomain conformational changes during its activation processes. Specifically, Akt-membrane interaction induced an open interdomain conformation where the PH and RD domains moved away from the kinase domain, allowing access of PDKs to T308 and S473 for Akt phosphorylation and activation.

In the present study, we applied the cross-linking and mass spectrometric approaches to probe the mechanism of Akt interactions with Akt inhibitors. The inhibitors used in this study are designed to interfere with Akt-membrane interaction, and are supposedly promising anticancer drugs in terms of superior specificity and less toxicity compared with those known to compete with ATP binding [12]. By quantitative comparisons of Akt conformational changes using two interdomain cross-linked peptides, K30(PH)-K389(KD) and K284(KD)-K426(RD), we were able to suggest distinctively different molecular mechanisms by which these inhibitors function.

Experimental

Materials

Inactive Akt1 and ATP/ Mg^{2+} cocktail were purchased from Upstate Cell Signaling Solutions (Lake Placid, NY). Disuccinimidyl suberate (DSS) was purchased from Pierce (Rockford, IL). α -Cyano-4-hydroxycinnamic acid was purchased from Agilent Technologies (Wilmington, DE). Sequencing grade modified trypsin was purchased from Promega (Madison, WI). Immobilized trypsin was obtained from Applied Biosystems (Foster City, CA). Akt inhibitors (PI analog, cat. no. 124005 and TCL1 peptide, cat. no. 124013) and active PDK1 were purchased from EMD Chemical, Inc. (Gibbstown, NJ). 1-Stearoyl-2-docosahexaenoyl-*sn*-glycero-3-phospho-L-serine (18:0, 22:6-PS), 1-stearoyl-2-docosahexaenoyl-*sn*-glycero-3-phosphoethanolamine (18:0, 22:6-PE), 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (16:0, 18:1-PC), and 1-stearoyl-2-arachidonoyl-*sn*-glycero-3-phosphoinositol-3,4,5-trisphosphate (18:0, 20:4-PIP3) were purchased from Avanti Polar Lipids (Alabaster, AL). Pure water was obtained from a Gemini high purity water system (West Berlin, NJ). H_2^{18}O (99%), cyclohexane, 2,6-di-*tert*-butyl-*p*-cresol (BHT), and diethylenetriamine pentaacetic acid (DTPA) were purchased from Sigma (St. Louis, MO).

Other reagents were purchased from Sigma or Quality Biological, Inc. (Gaithersburg, MD).

Preparation of Unilamellar Vesicles

Unilamellar vesicles (1 mg/mL) composed of PC/PE/PS/PIP3 (19.8%/50%/30%/0.2%, which approximates a lipid composition in the inner leaflet of neuronal plasma membrane), were prepared according to the method reported previously [36]. Briefly, 1 mg/mL solutions of PE (18:0, 22:6), PC (16:0, 18:1), PS (18:0, 22:6), and PIP3 (18:0, 20:4) were mixed at the desired proportion. The mixture was dried under an N_2 steam, re-dissolved in 2 mL cyclohexane containing 75 μM BHT (2,6-di-*tert*-butyl-*p*-cresol) and lyophilized for 1–2 h under vacuum. The sample was reconstituted in 1 mL of PBS (pH 7.4) in the presence of 50 μM DTPA (diethylenetriamine pentaacetic acid). The lipid suspension was extruded 11 times through a 0.1 μm polycarbonate membrane (Corning, Inc., Corning, NY) using an Avanti mini-extruder (Avanti Polar Lipids, Alabaster, AL). All of the above procedures were carried out in an argon box except the drying and lyophilizing steps. An aliquot of the sample was analyzed by high-performance liquid chromatography-mass spectrometry (HPLC/MS) to verify the final concentrations of lipid components [37].

Cross-Linking Reaction, Tryptic Digestion, and ^{18}O Labeling

Akt sample at 5 μM was dialyzed overnight against 50 mM HEPES (pH 7.4) containing 50 mM NaCl at 4 °C to remove the primary amine-containing Tris-HCl buffer. Five μL of Akt was incubated with 30 μL liposomes in PBS containing 50 μM DTPA at 30 °C for 40 min in the presence or absence of 20 mM CaCl_2 . Alternatively, Akt was incubated at 30 °C for 30 min with either PI analog inhibitor (25 μM), or TCL1 peptide inhibitor (25 and 50 μM), based on the optimal concentration range reported for the inhibitors [18, 19], followed by additional incubation with 30 μL liposomes for 40 min at 30 °C. The mixture was incubated with a 50-M excess of freshly prepared DSS in DMSO (1% final concentration of DMSO) at room temperature for 10 min. At this cross-linking condition, inter-molecular cross-linked dimers or multimers were not observed according to SDS-PAGE analysis. The cross-linking reaction was quenched by adding 1 M Tris-HCl (pH 7.4) to a final concentration of 50 mM. The sample was digested with sequencing grade modified trypsin at 37 °C for 18 h using a trypsin to protein ratio of 1:20. After desalting, the sample was lyophilized to dryness.

$^{16}\text{O}/^{18}\text{O}$ labeling was carried out similar to the method previously reported [38]. The dried peptides were reconstituted with 20 μL of acetonitrile and 100 μL of 50 mM NH_4HCO_3 in either regular H_2^{16}O water or 99% H_2^{18}O . One μL of 1 M CaCl_2 and 5 μL of immobi-

lized trypsin were added to the digests. The mixtures were continuously rotated in an incubator at 30 °C for 30 h. After centrifuging the samples at 15,000 *g* for 5 min, supernatant was collected and acidified using TFA solution to pH 3.5. The samples were concentrated using a SpeedVac (Thermo Savant, Holbrook, NY) and desalted with C18 Ziptip (Millipore Corp., Billerica, MA) before mass spectrometric analysis.

MALDI-TOF/TOF MS Analysis

One μL of peptide mixture was mixed with 1 μL of matrix solution (α -cyano-4-hydroxycinnamic acid) and then spotted on a MALDI plate. Samples were allowed to air dry and were analyzed by a 4700 MALDI-TOF/TOF proteomics analyzer (Applied Biosystems, Foster City, CA) operated in reflector positive ion mode. The UV laser (Nd:YAG) was operated at 200 Hz with wavelength of 355 nm. For MS analysis, 1000–4000 *m/z* mass range was used, typically with 2000 shots per spectrum. A 1-keV collision energy was used in MS/MS acquisition for precursor ions of interest. Both MS and MS/MS data were acquired using the instrument default calibration. All acquired spectra were processed using 4000 Series Explore software (Applied Biosystems) in a default mode.

Nano-Electrospray Ionization (ESI) Mass Spectrometric Analysis

Desalted peptides were analyzed by a high-resolution QSTAR pulsar Qq-TOF mass spectrometer (Applied Biosystems/MDS SCIEX, Toronto, CA) equipped with a nano-electrospray ionization source. The ion source voltage was set to 1100 V in the positive ion mode. A full mass spectrum was acquired over an *m/z* range of 500–2000. Ions of interest were subjected to collision-induced dissociation (CID) using high purity nitrogen to obtain MS/MS data. Resolution greater than 8000 and mass accuracy with less than 30 ppm error were attained in both full MS and MS/MS modes. The reconstructed mass spectral data were generated using Analyst QS 1.1 software (Applied Biosystems/MDS SCIEX).

Analysis of the Cross-Linked Peptides

The cross-linked peptides were identified by comparing the mass spectrum obtained from DSS-modified sample with nonmodified control, followed by MS/MS analysis to determine the cross-linked lysine residues. Protein analysis work sheet (PAWS) was used to assign the mass values of tryptic peptides. MS/MS data for the cross-linked peptides were manually interpreted with the assistance of PAWS, Analyst QS 1.1 software, and ^{18}O labeling.

Results and Discussion

MALDI-TOF/TOF MS Analysis of Cross-Linked Peptides and Stable Isotope ^{18}O Labeling Using Immobilized Trypsin

Using ESI MS/MS, we have previously identified seven intramolecular cross-linked lysine pairs in inactive Akt molecule, including K111-K112, K214-K284, K158-163, K30-K39, K377-K385, K30-K389, and K284-K426 [15]. The cross-linking results obtained by MALDI-TOF/TOF MS were in agreement with the previous ESI MS data, with the exception of a cross-linked peptide with mass of 3623 Da (K214–K284). This cross-linking was detected by ESI but not MALDI, presumably due to discrepancy in the ionization efficiency. Figure 1a represents the MALDI TOF/TOF mass spectra of the tryptic digests of inactive Akt samples with a mass range of 2300–3500 Da. The mass window was chosen to simplify the spectra because the peaks of interest are within this range. Four cross-linked peptides with *m/z* value of 2459.4, 2940.6, 3121.6, and 3465.9, representing the intramolecular cross-linking of K30(PH)-K389(KD), K30(PH)-K39(PH), K111(PH)-K112(PH), and K284(KD)-K426(RD), respectively, were observed in the DSS-modified sample, whereas they were absent in the nonmodified control (data not shown). Based on the distance constraints of 24 Å rendered by the cross-linking agent DSS, the presence of two interdomain cross-linked pairs, K30(PH)-K389(KD) and K284(KD)-K426(RD), represents the proximity of the PH and the regulatory domain to the central kinase domain. Quantitative monitoring of these two cross-linked peptides using ^{18}O labeling can be used to probe the interdomain conformational changes of Akt [15].

A key challenge in proteolytic ^{18}O labeling for quantitative MS is to overcome the incomplete incorporation of ^{18}O atoms into the C-terminal of lysine or arginine [33]. From our previous experience with the labeling procedure using protein digestion in 99% ^{18}O water [15, 32], we have learned that removing salts and excess chemical reagents via dialysis is critical for full incorporation of ^{18}O atoms, despite reduced protein recovery. The current study employed an alternative approach of labeling tryptic peptides using immobilized trypsin in 99% ^{18}O water as described in the Experimental section [38]. This post-digestion labeling procedure resulted in complete ^{18}O incorporation, as shown in Figure 1b. The non-cross-linked peptide increased by 4 Da (e.g., MH^+ 2891.6 for T[87–111]K), as the case with the internal cross-linking within a peptide segment because a total of 2 ^{18}O atoms were incorporated into the single C-terminal. However, due to two C-termini from two different tryptic peptide segments (Figure 1 inset), the *m/z* value of the interdomain cross-linked peaks shifted by 8 to 2467.4 and 3473.9 (Figure 1b), respectively. The identity of the peaks was further confirmed by MS/MS analysis using the ESI mode, which resulted in a better sequence coverage than

Figure 1. MALDI-TOF-TOF MS spectra of DSS-modified tryptic digests labeled with ^{16}O (a) or ^{18}O (b). Newly emerging cross-linked peptides are marked with asterisks. The MS data indicate a complete incorporation of ^{18}O atoms. Inset, Through-space cross-linked peptides between two peptide segments display a distinct 8 Da shift when labeled with ^{18}O .

MALDI. For example, the ESI MS/MS data obtained from the peptide with mass of 2466 Da (derived from triply charged ion of 823.1 m/z , Figure 2 inset) confirmed the peptide was due to the cross-linking between K30 of Y[26–39]K to K389 of D[387–391]R, with the C-terminal of K39 and R391 each labeled with two ^{18}O atoms (Figure 2). Although quantitative analysis was our purpose of using ^{18}O labeling in the study, an additional benefit of the labeling was also clear in the sequence assignment, especially from complicated MS/MS spectra of cross-linked peptides. As shown in Figure 2, in comparison with MS/MS spectrum of the ^{16}O counterpart (peak values are listed in the parentheses), an m/z shift of 4 in singly charged peaks indicated that they were y ions (e.g., m/z 789.43, inset) originating from one of the cross-linked peptides. Likewise, an m/z increase of 4 in doubly charged peaks (e.g., m/z 966.02, inset) indicated they were y ions containing both C-termini from the cross-linked peptide segments. It is apparent that the peaks with an unchanged m/z value resulted from the cleavage from N-terminal such as b or a ions. These characteristics of ^{18}O labeling in conjunction with MS/MS enabled us to unambiguously assign the cross-linking sites in the through-space cross-linked peptides.

Probing the Inhibition of Interdomain Conformational Changes Due to Disruption of Akt-Membrane Interaction by Ca^{2+}

The mass spectrometric analysis of cross-linked peptides provides not only a tool to monitor conformational changes of Akt during activation [15] but also a strategy to investigate Akt-membrane and/or Akt-inhibitor interactions. An example is shown for the effect of calcium on membrane-induced Akt conformational changes and activation. The ^{18}O labeling tryptic peptides from the nonmembrane interacted control were mixed with ^{16}O labeled digests from the liposome-interacted samples and subjected to MALDI analysis (Figure 3a). As shown in Figure 3b, the relative amount of the control and membrane-interacted samples was calculated by the average $^{16}\text{O}/^{18}\text{O}$ ratio of the isotopic pairs of the six non-cross-linked peptides, including C[77–86]R, Y[215–222]R, V[145–154]K, F[407–419]K, L[347–356]K, and T[87–111]K, using a formula ($^{16}\text{O}/^{18}\text{O}$ ratio = $I_0/[I_4 - (M_4/M_0)I_0]$), which is a modified form of the previous equation [33] based on the complete exchange of ^{18}O in our experiments. In the equation, I_0 and I_4 are the observed relative intensities for the monoisotopic peak for the peptide without ^{18}O label

Figure 2. ESI MS/MS analysis of the ^{18}O labeled cross-linked peptide with mass of 2466 Da reconstituted from the triply charged ion of m/z 823.1. The sequence of the peptide was assigned with single letter abbreviation based on the fragment ions observed for the cross-linked peptide segments. N-terminal b ions and C-terminal y ions resulting from the amide bond cleavage are labeled. The MS/MS spectrum indicates that K30 of the peptide segment Y [26–39]K (designated as α) linked to K389 of D [387–391]R (designated as β), via C₈H₁₀O₂, the cross-linking bridge from DSS, with C-terminal of K39 and R391 labeled with ^{18}O . ^{18}O labeling facilitated the assignment of the fragment ions. The m/z values for the fragment ions are labeled (the m/z values obtained from ^{16}O labeling are listed in parentheses). Inset shows the charged state for the indicated ions.

and the peak with 4 Da higher mass, respectively; M_0 and M_4 are the theoretical relative intensities for the monoisotopic peak and the peak with 4 Da higher mass, respectively. The average ratio of $^{16}\text{O}/^{18}\text{O}$ from the six non-cross-linked peptides was found to be 1.05 ± 0.10 in this case as shown in Table 1. The peptide cross-linked at K30–K389 or K284–K426 digested in H_2^{16}O was not detected (m/z 2459 or 3466), whereas their counterparts digested in H_2^{18}O (2467 or 3474 Da) were detected, confirming the absence of the cross-linking of K30–K389 and K284–K426 in the membrane-interacted sample. The individual capping of the cross-linked lysine residues was observed even in the presence of the cross-linked peptides (e.g., K284- and K426-capping, Figure 3b), presumably because the cross-linking reaction as well as the hydrolysis of the unreacted end of the bifunctional cross-linker occurs rapidly. This could explain relatively minor changes observed for the mono-links despite the reduced cross-linked pairs in many

experiments. Nevertheless, in extreme cases where the interdomain cross-linked peptides disappeared, we observed a slight increase in the mono-links. Such example is shown in Figure 3b, where K284- and K426-capping increased by $\sim 20\%$ (Table 1) when K284–K426 cross-linking was lost upon the membrane interaction, suggesting that solvent accessibility to these lysine residues is similar after membrane interaction. As described previously [15], the absence of the interdomain cross-linking suggested that Akt-membrane interaction caused open interdomain conformations, where the PH and RD domains unfold from the kinase domain to expose T308 and S473 for subsequent phosphorylation and Akt activation (Figure 3b, schematic presentation). However, when Akt was incubated with the vesicles in the presence of 20 mM Ca^{2+} , which is known to disrupt the surface charge of the membrane [39], the two interdomain cross-linked pairs were observed again in the mass spectrum (Figure 3c) at an extent comparable

Figure 3. Quantitative analysis of the interdomain cross-linked peptides upon Akt-membrane interaction. (a) A quantitative analysis scheme. (b) and (c) MALDI-TOF-TOF MS spectrum obtained from ^{16}O -labeled membrane-interacted sample without (b) or with Ca^{2+} (c), mixed with ^{18}O -labeled noninteracted control. The schematic presentation illustrates the interdomain conformational changes of Akt caused by membrane interaction in the absence or presence of Ca^{2+} .

to the noninteracted control, as indicated by the $^{16}\text{O}/^{18}\text{O}$ ratio normalized to the average value from six nonmodified peptides (Table 2). This result strongly suggested that the Akt-membrane interaction was indeed disrupted by Ca^{2+} , preventing conformational changes of Akt to an open conformer.

Akt Conformational Changes Caused by Interaction with a Phosphatidylinositol (PI) Analog

Figure 4a shows the changes of the interdomain cross-linking after Akt interacted with an Akt inhibitor, a phosphatidylinositol (PI) analog. The sample was ob-

Table 1. Quantitation of cross-linked peptides upon membrane interaction

^{16}O labeled sample ^a	Ratio	PH-KD	T[87-111]K	RD-KD	K284-cap	K426-cap	Average ratio ^b
Akt + liposomes	$^{16}\text{O}/^{18}\text{O}$ (from Fig. 3b)	0	1.12	0	1.32	1.30	1.05 ± 0.10
	$^{16}\text{O}/^{18}\text{O}$ nor. ^c	0	1.10	0	1.26	1.24	
	$^{16}\text{O}/^{18}\text{O}$ ave. ($n = 3$) ^d	0	0.96 ± 0.10	0	1.21 ± 0.19	1.19 ± 0.13	

^aThe ^{16}O labeled sample was mixed with ^{18}O labeled Akt control for MS analysis.

^bAverage value for six nonmodified peptides.

^cNormalized to the average value for six nonmodified peptides.

^dAverage normalized ratios from three measurements. The data are representative of three independent experiments.

Table 2. Quantitation of cross-linked peptides upon inhibitor and/or membrane interaction

¹⁶ O labeled sample ^a	Ratio	PH-KD	T[87-111]K	RD-KD	Average ratios ^b
Akt + Ca ²⁺ + liposomes	¹⁶ O/ ¹⁸ O (from Fig. 3c)	0.68	0.65	0.72	0.67 ± 0.10
	¹⁶ O/ ¹⁸ O nor. ^c	1.01	0.97	1.07	
	¹⁶ O/ ¹⁸ O ave. (n = 3) ^d	0.83 ± 0.17	0.99 ± 0.02	0.93 ± 0.15	
Akt + PI analog	¹⁶ O/ ¹⁸ O (from Fig. 4a)	0.49	1.04	0.48	1.04 ± 0.10
	¹⁶ O/ ¹⁸ O nor. ^c	0.48	1.00	0.47	
	¹⁶ O/ ¹⁸ O ave. (n = 3) ^d	0.53 ± 0.05	1.04 ± 0.04	0.49 ± 0.02	
Akt + PI analog + liposomes	¹⁶ O/ ¹⁸ O (from Fig. 4b)	0.46	1.12	0.41	1.02 ± 0.09
	¹⁶ O/ ¹⁸ O nor. ^c	0.45	1.10	0.40	
	¹⁶ O/ ¹⁸ O ave. (n = 3) ^d	0.49 ± 0.04	1.09 ± 0.01	0.43 ± 0.04	
Akt + TCL1	¹⁶ O/ ¹⁸ O (from Fig. 5a)	1.20	0.99	1.01	1.08 ± 0.13
	¹⁶ O/ ¹⁸ O nor. ^c	1.11	0.92	0.94	
	¹⁶ O/ ¹⁸ O ave. (n = 3) ^d	1.04 ± 0.08	0.98 ± 0.05	0.96 ± 0.02	
Akt + TCL1 + liposomes	¹⁶ O/ ¹⁸ O (from Fig. 5b)	0.42	0.52	0.25	0.56 ± 0.06
	¹⁶ O/ ¹⁸ O nor. ^c	0.75	0.93	0.45	
	¹⁶ O/ ¹⁸ O ave. (n = 3) ^d	0.70 ± 0.08	0.97 ± 0.04	0.42 ± 0.04	

^aThe ¹⁶O labeled sample was mixed with ¹⁸O labeled Akt control for MS analysis.^bAverage value for six nonmodified peptides.^cNormalized to the average value for six nonmodified peptides.^dAverage normalized ratios from three measurements. The data are representative of at least two independent experiments.

tained by mixing ¹⁶O tryptic digests of the inhibitor-interacted sample with the ¹⁸O labeled digest of the noninteracted control. When Akt was interacted with the PI analog, both PH-KD and RD-KD cross-linking pairs decreased considerably compared with the ¹⁸O labeled control (normalized ¹⁶O/¹⁸O ratios were 0.53 and 0.49, respectively, Table 2), indicating that the PI analog bound to Akt and induced an open interdomain conformation. The inhibitor is one of six 3-(hydroxymethyl)-bearing PI ether lipid analogs that have been shown to inhibit both PI3-K and Akt kinase activity in various cancer cell lines, presumably by preventing PIP3 formation or interfering with Akt-PIP3 interaction [18]. Interestingly, among these analogs that differ in structural combinations of a modified carbonate group and the position of -CH₂OH in the inositol head group, the PI analog used in this study is the most effective inhibitor for Akt but is the worst at inhibiting PIK3 kinase activity, although detailed mechanisms are not clear [18]. Our cross-linking results supported that this PI analog caused Akt conformational changes as in the case with the membrane-interacted Akt (schematic presentation in Figure 4), even before the membrane interaction, by binding to Akt. It is expected that the Akt-inhibitor interaction competes with the interaction of Akt with membrane PIP3, consequently preventing cytosolic Akt from translocating to the plasma membrane for the interdomain conformational changes for subsequent phosphorylation. This notion was supported by the fact that the extent of interdomain cross-linking observed after Akt-PI interaction remained similar even in the presence of liposomes (Figure 4b and Table 2). This mechanism provided an explanation for the reported strong potency of the inhibitor for Akt

activity in living cells, despite its minimal inhibitory activity against PI3 kinase.

Effect of Akt Inhibitor (Proto-Oncogene TCL1 Peptide) on Akt-Membrane Interaction Revealed by Conformational Changes

The interdomain cross-linking was analyzed after Akt was interacted with an inhibitor named TCL1 peptide, in comparison with noninteracted control (Figure 5a). The inhibitor consists of 15 amino acids, which is equivalent to A[10–24]F of the βA strand of the proto-oncogene TCL1, an Akt-interacting protein. The ¹⁶O tryptic digests obtained from the inhibitor-interacted sample was mixed with the ¹⁸O labeled digest from the noninteracted control with a ratio of ~1:1. The intensity of the interdomain cross-linked pairs did not change significantly after Akt was incubated with the peptide inhibitor, as indicated in the normalized ¹⁶O/¹⁸O ratios (Table 2). The peptide is thought to bind to the PH domain of Akt, similar to the case with wild type TCL1. Nuclear magnetic resonance (NMR) studies have suggested that the peptide induces a local conformational change in the variable loop 1 (VL1, residues 10–20) of the Akt PH domain [19], an important region for PIP3 binding [27]. Although the detailed local 3D structural changes could not be probed by the current cross-linking strategy, our data indicated that the peptide binding did not induce an open interdomain conformation. The peptide inhibitor has been shown to greatly impair the membrane translocation of the Akt PH domain and phosphorylation of T308 and S473 in 293 cells after stimulation with platelet-derived growth factor (PDGF) [19]. This inhibition has been attributed to its ability to interfere with the interaction of Akt with

Figure 4. Quantitative analysis of the interdomain cross-linked peptides upon Akt-inhibitor (PI analog) interaction. MALDI-TOF-TOF MS spectrum was obtained from ^{16}O -labeled inhibitor-interacted sample without (a) or with liposomes (b), mixed with ^{18}O -labeled noninteracted control. The schematic presentation illustrates the effect of the inhibitor on Akt interdomain conformation and membrane translocation.

membrane PIP3. Our cross-linking data, shown in Figure 5b, were consistent with this view. When inactive Akt was incubated with liposomes in the presence of TCL1 peptide at 25 μM , the interdomain cross-linked peptides did not disappear, in contrast to the case where Akt was incubated with liposomes without inhibitors (Figure 3b). The normalized $^{16}\text{O}/^{18}\text{O}$ ratios were 0.70 and 0.42 for the PH-KD and RD-KD cross-linked peptides, respectively (Table 2). The presence of these cross-linking pairs indicated that considerable proportions of both PH and RD domains remained folded even after membrane interaction, suggesting that conformational change to an open Akt conformer was impaired by the TCL1 inhibitor (Figure 5). In the

presence of TCL1 inhibitor, RD appeared to interact with membrane better than the PH domain, as around 60% of Akt population showed an open RD-KD conformation. A significant reduction of PIP3-PH interaction is expected, based on the previous observation of the peptide inhibitor spanning the binding site of the PH domain [19]. As 25 μM TCL1 partially prevented the conformational changes upon membrane interaction, we evaluated the effect of TCL1 at a higher concentration (50 μM). We observed a modest increase of the PH-KD and RD-KD cross-linking ($^{16}\text{O}/^{18}\text{O}$ ratios were 0.80 ± 0.02 and 0.52 ± 0.05 , respectively), suggesting a better inhibition of Akt open conformation with a higher dose of TCL1 peptide.

Figure 5. Quantitative analysis of the interdomain cross-linked peptides upon Akt-inhibitor (TCL1 peptide) interaction with or without the presence of membrane. MALDI-TOF-TOF MS spectrum was obtained from ^{16}O -labeled inhibitor-interacted sample without (a) or with liposomes (b), mixed with ^{18}O -labeled noninteracted control. The schematic presentation illustrates the effect of the peptide inhibitor on Akt interdomain conformation and membrane translocation.

Conclusions

We demonstrated that Akt interdomain conformational changes provide a molecular mechanism for the Akt-membrane interaction, which is a prerequisite step for Akt activation. We presented here a novel strategy to study the interaction between Akt and its inhibitors by probing the conformational changes of Akt, using chemical cross-linking and ^{18}O labeling mass spectrometry. Our cross-linking strategy suggested two distinctive molecular interaction mechanisms involved in Akt inhibition. The PI analog caused conformational changes upon interaction with Akt even before membrane interaction, subsequently disabling Akt translocation to the membrane. In contrast, the TCL1 peptide

interfered at the stage of Akt-membrane interaction, particularly impairing the unfolding of the PH domain. This novel approach should be potentially useful in facilitating drug discovery efforts for specific Akt inhibitors or antitumor agents based on the underlying molecular interaction mechanisms.

References

1. Brazil, D. P.; Hemmings, B. A. Ten Years of Protein Kinase B Signaling: A Hard Akt to Follow. *Trends Biochem. Sci.* **2001**, 26, 657–664.
2. Lawlor, M. A.; Alessi, D. R. PKB/Akt: A Key Mediator of Cell Proliferation, Survival, and Insulin Responses? *J. Cell Sci.* **2001**, 114, 2903–2910.
3. Cantley, L. C. The Phosphoinositide 3-kinase Pathway. *Science* **2002**, 296, 1655–1657.

4. Datta, S. R.; Dudek, H.; Tao, X.; Masters, S.; Fu, Haian; Gotoh, Y.; Greenberg, M. E. Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery. *Cell* **1997**, *91*, 231–241.
5. Cardone, M. H.; Roy, N.; Stennicke, H. R.; Salvesen, G. S.; Franke, T. F.; Stanbridge, E.; Frisch, S.; Reed, J. C. Regulation of Cell Death Protease Caspase-9 by Phosphorylation. *Science* **1998**, *282*, 1318–1321.
6. Brunet, A.; Bonni, A.; Zigmond, M. J.; Lin, M. Z.; Juo, P.; Hu, L. S.; Anderson, M. J.; Arden, K. C.; Blenis, J.; Greenberg, M. E. Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor. *Cell* **1999**, *96*, 857–868.
7. Govindarajan, B.; Sligh, J. E.; Vincent, B. J.; Li, M.; Canter, J. A.; Nickoloff, B. J.; Rodenburg, R. J.; Smeitink, J. A.; Oberley, L.; Zhang, Y.; Slingerland, J.; Arnold, R. S.; Lambeth, J. D.; Cohen, C.; Hilenski, L.; Griendling, K.; Martinez-Diez, M.; Cuezva, J. M.; Jack, L.; Arbiser, L. Overexpression of Akt Converts Radial Growth Melanoma to Vertical Growth Melanoma. *J. Clin. Invest.* **2007**, *117*, 719–729.
8. Nicholson, K. M.; Anderson, N. G. The Protein Kinase B/Akt Signaling Pathway in Human Malignancy. *Cell Signal.* **2002**, *14*, 381–395.
9. Kondapaka, S. B.; Singh, S. S.; Dasmahapatra, G. P.; Sausville, E. A.; Roy, K. K. Perifosine, A Novel Alkylphospholipid, Inhibits Protein Kinase B Activation. *Mol. Cancer Ther.* **2003**, *2*, 1093–1103.
10. Crul, M.; Rosing, H.; de Klerk, G. J.; Dubbelman, R.; Traiser, M.; Reichert, S.; Knebel, N. G.; Schellens, J. H. M.; Beijnen, J. H.; ten Bokkel Huinink, W. W. Phase I and Pharmacological Study of Daily Oral Administration of Perifosine (D-21266) in Patients with Advanced Solid Tumours. *Eur. J. Cancer* **2002**, *38*, 1615–1621.
11. Yuan, Z. Q.; Sun, M.; Feldman, R. I.; Wang, G.; Ma, X.; Jiang, C.; Coppola, D.; Nicosia, S. V.; Cheng, J. Q. Frequent Activation of AKT2 and Induction of Apoptosis by Inhibition of Phosphoinositide-3-OH Kinase/Akt Pathway in Human Ovarian Cancer. *Oncogene* **2000**, *19*, 2324–2330.
12. Amaravadi, A.; Thompson, C. B. The Survival Kinases Akt and Pim as Potential Pharmacological Targets. *J. Clin. Invest.* **2005**, *115*, 2618–2624.
13. Alessi, D. R.; Cohen, P. Mechanism of Activation and Function of Protein Kinase B. *Curr. Opin. Genet. Dev.* **1998**, *8*, 55–62.
14. Yang, J.; Cron, P.; Thompson, V.; Good, V. M.; Hess, D.; Hemmings, B. A.; Barford, D. Molecular Mechanism for the Regulation of Protein Kinase B/Akt by Hydrophobic Motif Phosphorylation. *Mol. Cell* **2002**, *9*, 1227–1240.
15. Huang, B. X.; Kim, H.-Y. Interdomain Conformational Changes in Akt Activation Revealed by Chemical Cross-linking and Tandem Mass Spectrometry. *Mol. Cell. Proteom.* **2006**, *5*, 1045–1053.
16. Calleja, V.; Alcor, D.; Laguerre, M.; Park, J.; Vojnovic, B.; Hemmings, B. A.; Downward, J.; Parker, P. J.; Larijani, B. Intramolecular and Intermolecular Interactions of Protein Kinase B Define Its Activation In Vivo. *PLoS Biol.* **2007**, *5*, e95.
17. Barnett, S. F.; Defeo-Jones, D.; Fu, S.; Hancock, P. J.; Haskell, K. M.; Jones, R. E.; Kahana, J. A.; Kral, A. M.; Leander, K.; Lee, L. L.; Malinowski, J.; McAVOY, E. M.; Nahas, D. D.; Robinson, R. G.; Hans, E.; Huber, H. E. Identification and Characterization of Pleckstrin-Homology-Domain-Dependent and Isoenzyme-Specific Akt Inhibitors. *Biochem. J.* **2005**, *385*, 399–408.
18. Hu, Y.; Qiao, L.; Wang, S.; Rong, S.; Meuillet, E. J.; Berggren, M.; Gallegos, A.; Powis, G.; Kozikowski, A. P. 3-(Hydroxymethyl)-Bearing Phosphatidylinositol Ether Lipid Analogs and Carbonate Surrogates Block PI3-K, Akt, and Cancer Cell Growth. *J. Med. Chem.* **2003**, *43*, 3045–3051.
19. Hiromura, M.; Okada, F.; Obata, T.; Auguin, D.; Shibata, T.; Roumestand, C.; Noguchi, M. Inhibition of Akt Kinase Activity by a Peptide Spanning the BA Strand of the Proto-oncogene TCL1. *J. Biol. Chem.* **2004**, *279*, 53407–53418.
20. Bellacosa, A.; Testa, J. R.; Staal, S. P.; Tsichlis, P. N. A Retroviral Oncogene, Akt, Encoding a Serine-threonine Kinase Containing a SH2-like Region. *Science* **1991**, *254*, 274–277.
21. Thomas, C. C.; Deak, M.; Alessi, D. R.; van Aalten, D. M. F. High-resolution Structure of the Pleckstrin Homology Domain of Protein Kinase B/Akt Bound to Phosphatidylinositol (3,4,5)-Trisphosphate. *Curr. Biol.* **2002**, *12*, 1256–1262.
22. Stokoe, D.; Stephens, L. R.; Copeland, T.; Gaffney, P. R. J.; Reese, C. B.; Painter, G. F.; Holmes, A. B.; McCormick, F.; Hawkins, P. T. Dual Role of Phosphatidylinositol-3,4,5-Trisphosphate in the Activation of Protein Kinase B. *Science* **1997**, *277*, 567–570.
23. Andjelkovic, M.; Alessi, D. R.; Meier, R.; Fernandez, A.; Lamb, N. J. C.; Frech, M.; Cron, P.; Cohen, P.; Lucocq, J. M.; Hemmings, B. A. Role of Translocation in the Activation and Function of Protein Kinase B. *J. Biol. Chem.* **1997**, *272*, 31515–31524.
24. Bellacosa, A.; Chan, T. O.; Ahmed, N. N.; Datta, K.; Malstrom, S.; Stpkoe, D.; McCormick, F.; Feng, J. N.; Tsichlis, P. Akt Activation by Growth Factors is a Multiple-Step Process: The Role of the PH domain. *Oncogene* **1998**, *17*, 313–325.
25. Watton, S. J.; Downward, J. Akt/PKB Localization and 3' Phosphoinositide Generation at Sites of Epithelial Cell–Matrix and Cell–Cell Interaction. *Curr. Biol.* **1999**, *9*, 433–436.
26. Milburn, C. C.; Deak, M.; Kelly, S. M.; Price, S. M.; Alessi, D. R.; van Aalten, D. M. F. Binding of Phosphatidylinositol 3,4,5-Trisphosphate to the Pleckstrin Homology Domain of Protein Kinase B Induces A Conformational Change. *Biochem. J.* **2003**, *375*, 531–538.
27. Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Barford, D. Crystal Structure of an Activated Akt/Protein Kinase B Ternary Complex with GSK3-peptide and AMP-PNP. *Nat. Struct. Biol.* **2002**, *12*, 940–944.
28. Auguin, D.; Barthe, P.; Auge-Senegas, M.; Stern, M.; Noguchi, M.; Roumestand, C. Solution Structure and Backbone Dynamics of the Pleckstrin Homology Domain of the Human Protein Kinase B (PKB/Akt): Interaction with Inositol Phosphates. *J. Biomol. NMR* **2004**, *28*, 137–155.
29. Calleja, V.; Ameer-beg, S. M.; Vojnovic, B.; Woscholski, R.; Downward, J.; Larijani, B. Monitoring Conformational Changes of Proteins in cells by Fluorescence Lifetime Imaging Microscopy. *Biochem. J.* **2003**, *372*, 33–40.
30. Young, M. M.; Tang, N.; Hempel, J. C.; Oshiro, C. M.; Taylor, E. W.; Kuntz, I. D.; Gibson, B. W.; Dollinger, G. High Throughput Protein Fold Identification by Using Experimental Constraints Derived from Intramolecular Cross-Links and Mass Spectrometry. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 5802–5806.
31. Sinz, A. Chemical Cross-Linking and Mass Spectrometry for Mapping Three-Dimensional Structures of Proteins and Protein Complexes. *J. Mass Spectrom.* **2003**, *38*, 1225–1237.
32. Huang, B. X.; Dass, C.; Kim, H.-Y. Probing Three-Dimensional Structure of Bovine Serum Albumin by Chemical Cross-Linking and Mass Spectrometry. *J. Am. Soc. Mass Spectrom.* **2004**, *15*, 1237–1247.
33. Yao, X.; Freas, A.; Ramirez, J.; Demirev, P. A.; Fenselau, C. Proteolytic ¹⁸O labeling for Comparative Proteomics: Model Studies with Two Serotypes of Adenovirus. *Anal. Chem.* **2001**, *73*, 2836–2842.
34. Back, J. W.; Notenboom, V.; Koning, L. J.; Muijsers, A. O.; Sixma, T. K.; Koster, C. G.; Jong, L. Identification of Cross-linked Peptides for Protein Interaction Studies Using Mass Spectrometry and ¹⁸O labeling. *Anal. Chem.* **2002**, *74*, 4417–4422.
35. Huang, B. X.; Dass, C.; Kim, H.-Y. Probing Conformational Changes of Human Serum Albumin Due to Unsaturated Fatty Acid Binding by Chemical Cross-Linking and Mass Spectrometry. *Biochem. J.* **2005**, *387*, 695–702.
36. Kim, H.-Y.; Bigelow, J.; Kevala, J. H. Substrate Preference in Phosphatidylserine Biosynthesis for Docosahexaenoic Acid Containing Species. *Biochemistry* **2001**, *43*, 1030–1036.
37. Wen, Z.; Kim, H.-Y. Alterations in Hippocampal Phospholipid Profile by Prenatal Exposure to Ethanol. *J. Neurochem.* **2004**, *89*, 1368–1377.
38. Liu, T.; Qian, W.-J.; Strittmatter, E. F.; Camp, D. G.; Anderson, G. A.; Thrall, B. D.; Smith, R. D. High-Throughput Comparative Proteome Analysis Using a Quantitative Cysteine-Peptide Enrichment Technology. *Anal. Chem.* **2004**, *76*, 5345–5353.
39. Gomez, G. A.; Daniotti, J. L. Electrical Properties of Plasma Membrane Modulate Subcellular Distribution of K-Ras. *FEBS J.* **2007**, *274*, 2210–2228.